JPH11503998A - レチノイン酸受容体アゴニストによる網膜色素上皮の増殖の阻止方法 - Google Patents
レチノイン酸受容体アゴニストによる網膜色素上皮の増殖の阻止方法Info
- Publication number
- JPH11503998A JPH11503998A JP8523769A JP52376996A JPH11503998A JP H11503998 A JPH11503998 A JP H11503998A JP 8523769 A JP8523769 A JP 8523769A JP 52376996 A JP52376996 A JP 52376996A JP H11503998 A JPH11503998 A JP H11503998A
- Authority
- JP
- Japan
- Prior art keywords
- rar
- agonist
- rar agonist
- retinoic acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.網膜色素上皮(RPE)の増殖と関連した疾患の改善方法であって、それを 必要としている被験者の網膜色素上皮細胞を、レチノイン酸を除いた、治療量の レチノイン酸受容体(RAR)アゴニストと接触させることを含んでなる方法。 2.RARアゴニストが特異的なRARアゴニストである、請求項1に記載の方 法。 3.RARアゴニストがAP−1依存性遺伝子発現を実質的に抑制する、請求項 1に記載の方法。 4.RARアゴニストがエチル-6-[2-(4,4- ジメチルチオクロマン-6- イル)エ チニル]ニコチネート(化合物 168)である、請求項2に記載の方法。 5.RARアゴニストが 6-[2-(4,4- ジメチルクロマン-6- イル)エチニル]ニコ チン酸(化合物 299)である、請求項2に記載の方法。 6.RARアゴニストが p-[(E)-2-(5,6,7,8- テトラヒドロ-5,5,8,8- テトラメ チル-2- ナフチル)プロペニル]-安息香酸(化合物 183)である、請求項2に記 載の方法。 7.その結果として増殖性硝子体網膜症が実質的に阻止される、請求項1に記載 の方法。 8.RARアゴニストがAP−1依存性遺伝子発現のアンタゴニストでもある、 請求項1に記載の方法。 9.RARアゴニストが非内因性である、請求項1に記載の方法。 10.RARアゴニストを硝子体腔に注入する、請求項1に記載の方法。 11.治療量が約50〜150μg の範囲である、請求項1に記載の方法。 12.前記の接触が手術または外傷後約24時間以内に投与される1回量によるも のである、請求項11に記載の方法。 13.前記の接触が持続放出によるものである、請求項11に記載の方法。 14.持続放出が約3〜20日間である、請求項13に記載の方法。 15.RARアゴニストをリポソーム内に保持させる、請求項13に記載の方法。 16.RARアゴニストを微粒子に圧縮製剤化する、請求項13に記載の方法。 17.微粒子を強膜ポケットまたは結膜下腔に投与する、請求項16に記載の方法。 18.RARアゴニストを生物学的に不活性な液体に溶解する、請求項12に記載の 方法。 19.前記の液体がシリコーン油である、請求項18に記載の方法。 20.RARアゴニストが9−シス−レチノイン酸である、請求項1に記載の方法 。 21.網膜色素上皮(RPE)の増殖と関連した疾患の改善方法であって、それを 必要としている被験者の網膜色素上皮細胞を、治療量のAP−1アンタゴニスト と接触させることを含んでなる方法。 22.牽引性網膜剥離の改善方法であって、それを必要としている被験者の網膜色 素上皮細胞を、治療量のAP−1アンタゴニストと接触させることを含んでなる 方法。 23.牽引性網膜剥離の改善方法であって、それを必要としている被験者の網膜色 素上皮細胞を、治療量のレチノイン酸受容体(RAR)アゴニストと接触させる ことを含んでなる方法。 24.レチノイン酸を除いた、治療量のレチノイン酸受容体(RAR)アゴニスト を含有する、網膜色素上皮の増殖を治療するための組成物。 25.RARアゴニストが特異的なRARアゴニストである、請求項24に記載の組 成物。 26.RARアゴニストがエチル-6-[2-(4,4- ジメチルチオクロマン-6- イル)エ チニル]ニコチネート(化合物 168)である、請求項24に記載の組成物。 27.RARアゴニストがAP−1依存性遺伝子発現を実質的に抑制する、請求項 24に記載の組成物。 28.RARアゴニストが 6-[2-(4,4- ジメチルクロマン-6- イル)エチニル]ニコ チン酸(化合物 299)である、請求項27に記載の組成物。 29.RARアゴニストが p-[(E)-2-(5,6,7,8- テトラヒドロ-5,5,8,8- テトラメ チル-2- ナフチル)プロペニル]-安息香酸(化合物 183)である、請求項24に記 載の組成物。 30.網膜色素上皮細胞の増殖が実質的に抑制される、請求項24に記載の組成物。 31.脈絡膜新生血管形成と関連した眼の疾患の改善方法であって、それを必要と している被験者の網膜色素上皮細胞を、治療量のAP−1アンタゴニストと接触 させることを含んでなる方法。 32.眼の疾患が加齢に関係した黄斑変性である、請求項31に記載の方法。 33.眼の疾患がヒストプラスマ症候群である、請求項31に記載の方法。 34.脈絡膜新生血管形成と関連した眼の疾患の改善方法であって、それを必要と している被験者の網膜色素上皮細胞を、治療量のレチノイン酸受容体(RAR) アゴニストと接触させることを含んでなる方法。 35.眼の疾患が加齢に関係した黄斑変性である、請求項34に記載の方法。 36.眼の疾患がヒストプラスマ症候群である、請求項34に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/383,741 | 1995-02-01 | ||
US08/383,741 US5824685A (en) | 1995-02-01 | 1995-02-01 | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
PCT/US1996/001505 WO1996023498A1 (en) | 1995-02-01 | 1996-01-31 | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11503998A true JPH11503998A (ja) | 1999-04-06 |
JP4121552B2 JP4121552B2 (ja) | 2008-07-23 |
Family
ID=23514507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52376996A Expired - Fee Related JP4121552B2 (ja) | 1995-02-01 | 1996-01-31 | レチノイン酸受容体アゴニストによる網膜色素上皮の増殖の阻止方法 |
Country Status (7)
Country | Link |
---|---|
US (5) | US5824685A (ja) |
EP (1) | EP0804194B1 (ja) |
JP (1) | JP4121552B2 (ja) |
AT (1) | ATE291915T1 (ja) |
AU (1) | AU4707096A (ja) |
DE (1) | DE69634532T2 (ja) |
WO (1) | WO1996023498A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007525496A (ja) * | 2004-02-17 | 2007-09-06 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 黄班変性症を含む眼科疾患の管理 |
JP2008179648A (ja) * | 2004-12-08 | 2008-08-07 | Sirion Therapeutics Inc | レチノール関連疾患を処置するための方法、アッセイおよび組成物 |
US7432307B2 (en) | 2004-11-04 | 2008-10-07 | Sirion Therapeutics, Inc. | Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation |
JP2011518214A (ja) * | 2008-04-22 | 2011-06-23 | サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィク | メラニン形成を阻害するためのKif13A阻害剤およびAP−1阻害剤の使用 |
US8314152B2 (en) | 2004-06-23 | 2012-11-20 | Acucela, Inc. | Methods and compositions for treating ophthalmic conditions with retinyl derivatives |
WO2014188716A1 (ja) * | 2013-05-22 | 2014-11-27 | 国立大学法人山口大学 | 網脈絡膜障害の抑制剤 |
US9492431B2 (en) | 2012-11-08 | 2016-11-15 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2752734B1 (fr) * | 1996-09-02 | 1998-11-06 | Cird Galderma | Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf |
DE69739663D1 (de) | 1996-12-31 | 2009-12-31 | Antioxidant Pharmaceuticals Co | Pharmazeutische glutathionpräparate und methoden zu dern verabreichung |
DE69827138T2 (de) * | 1997-08-11 | 2006-02-23 | Allergan, Inc., Irvine | Steriles Retinoid enthaltendes biodegradierbares Implantat mit verbesserter Biokompatibilität und Verfahren zu dessen Herstellung |
US20030113281A1 (en) * | 1998-05-06 | 2003-06-19 | Galderma Research & Development, S.N.C. | Assay for identification of compounds that promote melanin production and retinoid-like compounds identified by said assay |
KR100538417B1 (ko) * | 1998-05-06 | 2005-12-22 | 갈데르마 리써어치 앤드 디벨로프먼트,에스.엔.씨. | 멜라닌 생성을 촉진하는 화합물의 확인을 위한 분석법 및그 분석법에 의해 확인되는 레티노이드류 화합물 |
US6146366A (en) * | 1998-11-03 | 2000-11-14 | Ras Holding Corp | Device for the treatment of macular degeneration and other eye disorders |
CA2350599A1 (en) * | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Method of inhibiting angiogenesis |
US6596500B1 (en) * | 1998-12-08 | 2003-07-22 | The General Hospital Corporation | Binding of retinoids to M6P/IGF-II receptor |
JP2005511713A (ja) * | 2001-12-07 | 2005-04-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 加齢性黄斑変性についての処置 |
US7470659B2 (en) * | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
US20030229062A1 (en) * | 2001-12-07 | 2003-12-11 | The Regents Of The University Of California | Treatments for age-related macular degeneration (AMD) |
WO2004028477A2 (en) * | 2002-09-29 | 2004-04-08 | Surmodics, Inc. | Methods for treatment and/or prevention of retinal disease |
US20060172972A1 (en) * | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
US20060166879A1 (en) * | 2002-12-20 | 2006-07-27 | Chakshu Research Inc | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
US7070554B2 (en) | 2003-01-15 | 2006-07-04 | Theragenics Corporation | Brachytherapy devices and methods of using them |
CN101039957A (zh) | 2003-05-16 | 2007-09-19 | 因特缪恩公司 | 合成的趋化因子受体配体及其使用方法 |
US20050009910A1 (en) * | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
WO2005040758A2 (en) * | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
CN1889954A (zh) * | 2003-12-02 | 2007-01-03 | 阿勒根公司 | 用类维生素a预防和/或减轻光受体变性的方法 |
US20080176952A1 (en) * | 2004-02-17 | 2008-07-24 | Rando Robert R | Management of Ophthalmologic Disorders, Including Macular Degeneration |
CA2601278C (en) * | 2004-03-17 | 2014-06-10 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle |
AU2005240078A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
WO2006014484A2 (en) * | 2004-07-02 | 2006-02-09 | Surmodics, Inc. | Methods and devices for the treatment of ocular conditions |
US20060020037A1 (en) * | 2004-07-22 | 2006-01-26 | Allergan, Inc. | Tazarotenic acid and esters thereof for treating autism |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
JP2008515778A (ja) * | 2004-08-18 | 2008-05-15 | シリオン セラピューティクス, インコーポレイテッド | 眼の状態を13−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療 |
WO2006110487A1 (en) * | 2005-04-08 | 2006-10-19 | Surmodics, Inc. | Sustained release implants for subretinal delivery |
UA81382C2 (en) * | 2005-07-11 | 2007-12-25 | Composition for treating retinol-related diseases by modulation of retinol binding | |
JP4756951B2 (ja) * | 2005-08-10 | 2011-08-24 | オリンパスメディカルシステムズ株式会社 | モノポーラ高周波処置装置 |
US20070254832A1 (en) * | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
US20080027031A1 (en) * | 2006-03-08 | 2008-01-31 | Kinemed, Inc. | Retinoids and Related Compounds for the Treatment of Neuroinflammatory Conditions, Diseases and Disorders |
US8916540B2 (en) * | 2008-01-15 | 2014-12-23 | Academia Sinica | Antibiotic compositions and related screening methods |
EP2323693B1 (en) * | 2008-07-30 | 2017-11-08 | Nitto Denko Corporation | Drug carriers |
CN102107158B (zh) | 2009-12-24 | 2013-03-20 | 同方威视技术股份有限公司 | 过滤装置、过滤方法以及痕量检测仪器 |
KR20150009541A (ko) * | 2012-04-16 | 2015-01-26 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 배아 줄기 세포 미소낭포를 이용한 안구 치료법 |
EP3967305A1 (en) | 2015-03-31 | 2022-03-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists |
DK3380086T3 (da) | 2015-11-25 | 2021-11-22 | Io Therapeutics Inc | Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer |
US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
MX2018012250A (es) | 2016-04-08 | 2019-06-24 | Syros Pharmaceuticals Inc | Agonistas de los receptores de acido retinoico alfa (rara) para el tratamiento de leucemia mieloide aguda (aml) y sindrome mielodisplasico (mds). |
EP4249490A3 (en) | 2016-06-08 | 2023-12-13 | Clementia Pharmaceuticals Inc. | Methods for treating heterotopic ossification |
AU2017278220C1 (en) | 2016-06-10 | 2022-10-13 | Io Therapeutics, Inc. | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
BR112019009929A2 (pt) | 2016-11-16 | 2019-08-20 | Clementia Pharmaceuticals Inc | métodos para inibir a formação de um osteocondroma, para reduzir o tamanho de um osteocondroma, para desacelerar o crescimento de um osteocondroma e para reduzir hiperplasia de cartilagem |
KR101782577B1 (ko) * | 2017-01-03 | 2017-09-28 | 윤성문 | 맥락막 질환의 치료를 위한 갑상선 호르몬의 용도 |
EP3651764A4 (en) | 2017-07-13 | 2021-09-22 | IO Therapeutics, Inc. | RETINOID AND REXINOID COMPOUNDS IMMUNOMODULATORS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY |
CN111148514A (zh) | 2017-08-31 | 2020-05-12 | Io治疗公司 | 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂 |
EP3709990A4 (en) * | 2017-11-17 | 2021-12-01 | The Regents of the University of California | MANIPULATION OF THE RETIC ACID SIGNAL PATH |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5234926A (en) * | 1987-03-20 | 1993-08-10 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
-
1995
- 1995-02-01 US US08/383,741 patent/US5824685A/en not_active Expired - Lifetime
-
1996
- 1996-01-31 DE DE69634532T patent/DE69634532T2/de not_active Expired - Lifetime
- 1996-01-31 EP EP96902791A patent/EP0804194B1/en not_active Expired - Lifetime
- 1996-01-31 WO PCT/US1996/001505 patent/WO1996023498A1/en active IP Right Grant
- 1996-01-31 AT AT96902791T patent/ATE291915T1/de not_active IP Right Cessation
- 1996-01-31 US US08/875,665 patent/US6075032A/en not_active Expired - Lifetime
- 1996-01-31 JP JP52376996A patent/JP4121552B2/ja not_active Expired - Fee Related
- 1996-01-31 AU AU47070/96A patent/AU4707096A/en not_active Withdrawn
-
1998
- 1998-10-20 US US09/175,192 patent/US6071924A/en not_active Expired - Lifetime
-
2000
- 2000-03-27 US US09/536,221 patent/US6372753B1/en not_active Expired - Fee Related
-
2001
- 2001-09-11 US US09/954,686 patent/US6573271B2/en not_active Expired - Fee Related
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007525496A (ja) * | 2004-02-17 | 2007-09-06 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 黄班変性症を含む眼科疾患の管理 |
US8314152B2 (en) | 2004-06-23 | 2012-11-20 | Acucela, Inc. | Methods and compositions for treating ophthalmic conditions with retinyl derivatives |
US8410168B2 (en) | 2004-06-23 | 2013-04-02 | Acucela, Inc. | Methods and compositions for treating ophthalmic conditions with retinyl derivatives |
US7432307B2 (en) | 2004-11-04 | 2008-10-07 | Sirion Therapeutics, Inc. | Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation |
JP2008179648A (ja) * | 2004-12-08 | 2008-08-07 | Sirion Therapeutics Inc | レチノール関連疾患を処置するための方法、アッセイおよび組成物 |
JP2011518214A (ja) * | 2008-04-22 | 2011-06-23 | サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィク | メラニン形成を阻害するためのKif13A阻害剤およびAP−1阻害剤の使用 |
US10537556B2 (en) | 2012-11-08 | 2020-01-21 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US9492431B2 (en) | 2012-11-08 | 2016-11-15 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US9750721B2 (en) | 2012-11-08 | 2017-09-05 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US10016395B2 (en) | 2012-11-08 | 2018-07-10 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US11471440B2 (en) | 2012-11-08 | 2022-10-18 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
JPWO2014188716A1 (ja) * | 2013-05-22 | 2017-02-23 | 国立大学法人山口大学 | 網脈絡膜障害の抑制剤 |
JP2018115221A (ja) * | 2013-05-22 | 2018-07-26 | 国立大学法人山口大学 | 網脈絡膜障害の抑制剤 |
WO2014188716A1 (ja) * | 2013-05-22 | 2014-11-27 | 国立大学法人山口大学 | 網脈絡膜障害の抑制剤 |
US10702502B2 (en) | 2013-05-22 | 2020-07-07 | Yamaguchi University | Inhibitor for retinochoroidal disorders |
US11730718B2 (en) | 2013-05-22 | 2023-08-22 | Yamaguchi University | Inhibitor for retinochoroidal disorders |
Also Published As
Publication number | Publication date |
---|---|
US6071924A (en) | 2000-06-06 |
JP4121552B2 (ja) | 2008-07-23 |
EP0804194A1 (en) | 1997-11-05 |
US20020128291A1 (en) | 2002-09-12 |
EP0804194B1 (en) | 2005-03-30 |
ATE291915T1 (de) | 2005-04-15 |
EP0804194A4 (en) | 2001-01-17 |
AU4707096A (en) | 1996-08-21 |
WO1996023498A1 (en) | 1996-08-08 |
US6372753B1 (en) | 2002-04-16 |
US6573271B2 (en) | 2003-06-03 |
DE69634532D1 (de) | 2005-05-04 |
US5824685A (en) | 1998-10-20 |
US6075032A (en) | 2000-06-13 |
DE69634532T2 (de) | 2006-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4121552B2 (ja) | レチノイン酸受容体アゴニストによる網膜色素上皮の増殖の阻止方法 | |
US6525087B2 (en) | Use of known agonists of the central cannabinoid receptor CB1 | |
EP0735868B1 (en) | Use of non-steroidal cyclooxygenase inhibitors for the manufacture of a medicament for the treatment of elevated intraocular pressure | |
DE69720745T2 (de) | Therapeutische kombinationen von rar-antagonisten und rxr-agonisten | |
US6632834B2 (en) | Compositions and methods for treating conditions responsive to estrogen | |
JP2000515523A (ja) | 創傷および線維性障害の治療における性ステロイド機能モジュレーターの使用 | |
CA1285878C (en) | Use of tetrahydrocortisol in glaucoma therapy | |
US20090093546A1 (en) | Method and Pharmaceutical Compositions for Treatment of Anti-Estrogen Resistant Breast Cancer Using RXR Modulators | |
JPH11511472A (ja) | Rxrアゴニストを用いたniddmの治療 | |
JP2001506638A (ja) | 白内障の予防または制御方法 | |
EP4141018A1 (en) | Peptide fg and its use in preparation of drugs for treating and preventing ocular fundus vascular diseases | |
CA2558199C (en) | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists | |
CA2209303C (en) | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists | |
WO2022052454A1 (zh) | 含酯基芳香丙酰胺类化合物在制备治疗干眼症药物中的应用 | |
EP4094765A1 (en) | Compounds for treatment of eye diseases associated with excessive vascularisation | |
JPH09301891A (ja) | 眼軸長制御剤、近視または遠視の予防および治療剤 | |
KR20150048880A (ko) | 눈 컨디션의 치료 및/또는 예방을 위한 조성물 및 방법에 있어서 siRNA 및 이의 용도 | |
CA2177578C (en) | Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060801 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061026 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070201 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070718 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080306 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080401 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080430 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110509 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110509 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120509 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120509 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130509 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140509 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |